Medicine used in the Treatment of Obesity

Slides:



Advertisements
Similar presentations
Addressing Obesity and Exercise in Primary Care GSP 4 th Year Elective 2010.
Advertisements

1 Evaluation of Obesity Associate Prof. Dr. Memet IŞIK Ataturk University Medical Faculty Department of Family Medicine
State-by-State Treatment of Obesity Interventions Christine Ferguson Professor George Washington University School of Public Health and Health Services.
Weighing the Evidence on Obesity
Assessment of Overweight and Obesity and the Need for Weight Loss Dr. David L. Gee FCSN/PE 446 Nutrition, Weight Control & Exercise.
Obesity.
Effect of Obesity on Kidney Transplantation Reference: Potluri K, Hou S. Obesity in kidney transplant recipients and candidates. Am J Kidney Dis. 2010;56:143–156.
Farxiga™ - Dapagliflozin
Data Supplement RIO-Europe RIO-Lipids RIO-Diabetes RIO-North America European labeling.
Department of Biochemistry Faculty of Pharmacy Suez Canal University.
LDL Cholesterol Goals and Cutpoints for Therapeutic Lifestyle Changes (TLC) and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL)
The Skinny On Weight Loss Drugs Siggi Ming, ARNP, NP-C Weight Loss Center of Oklahoma.
Epanova ® - Omega-3- carboxylic acids Manufacturer: AstraZeneca FDA Approval Date: 05/2014.
Bariatric Surgery Mr B.M.Axisa Consultant Laparoscopic and Upper GI Surgeon.
“Obesity is a medical condition in which excess body fat has accumulated to the extent that it may have an adverse effect on health” ("Obesity." Wikipedia)
THE PHARMACOLOGY OF OBESITY DR. HANIN OSAMA. DEFINITION OF OBESITY BMI (Grade 1, overweight) BMI (Grade 2, obese) BMI > 40 (Grade 3, Morbidly.
Obesity: A Metabolic Perspective. Obesity Trends* Among U.S. Adults BRFSS, 1985 (*BMI ≥30, or ~ 30 lbs overweight for 5’ 4” person) No Data
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 82 Drugs for Weight Loss.
Management of Obesity and Dyslipidemia Presented by : Faisal Hassan Hussain.
Louis boiron Alexandre diart
Obesity- Weight Management. Objectives Define obesity or overweight List health effects of obesity Explain possible causes of obesity Outline exercise.
Medical Management of obesity Perinatal ANGELS Conference Feb 17, 2005 Philip A. Kern.
Management of Obesity Promotion of increased physical activity and it’s maintenance on a long term, walking briskly for 30 minute each day can result in.
Evidence-Based Weight Management Guideline M.E.Khamseh Institute of Endocrinology and Metabolism Iran University of Medical Sciences.
OBESITY Babes-Bolyai University, Cluj-Napoca Faculty of Chemistry and Chemical Engineering Contra Gabriela Dobie Cristina Macec Rucsandra.
Long-Term Efficacy of Dapagliflozin in T2DM Patients Receiving High-Dose Insulin John P.H. Wilding, DM, FRCP

Obesity –Pharmacological treatments. Dietary management –A low energy,low fat diet is the most effective lifestyle intervention for weight loss Exercise.
VA/DoD 2006 Clinical Practice Guideline For Screening and Management of Overweight and Obesity Guideline Summary: Key Elements.
ANTI OBESITY PRESCRIBING 19 th November 2013 V.Welch.
Why bother? If you are male and obese you are 5 times more likely to develop diabetes than if you were at a healthy weight; if you are female and obese,
Moving Toward a Healthy Weight Lesson 2. Obesity is defined as having too much body fat.
The entwined factors Syndrome X. hypertension diabetes heart disease “trunkal” obesity cancers of all types Gene that lends predisposition to Syndrome.
Orlistat 60 mg Joint Meeting Nonprescription Drugs and Endocrinologic and Metabolic Drugs Advisory Committees January 23, 2006 Andrea Leonard-Segal, M.D.
Rivastigmine Tartrate Presented by: Mona Abdulrahman Alkallabi Mona Abdulrahman Alkallabi.
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
Physical Activity and Weight Management Julie Hagel, Pharm.D. September 24, 2003.
JESSICA FORDHAM, MSN, APRN, FNP-C MISSISSIPPI UNIVERSITY FOR WOMEN 12/02/14 TREATING OBESITY PHARMACOLOGICALLY.
+ Weight Loss Amber Frick, PharmD April 22, 2012.
Discuss prevention strategies and treatments for overeating and obesity.
Testimony of Sidney M. Wolfe MD and Elizabeth Barbehenn, Ph.D., Public Citizen’s Health Research Group FDA Non-Prescription and Endocrine and Metabolic.
Obesity By: Dr. Wael Thanoon C.A.B.M. College of medicine,Mosul University.
CDA exercise guidelines 150 minutes moderate – intensity (60 – 70% of max) aerobic over minimum 3 non consecutive days PLUS resistance exercise 3.
DRUGS Prescription, OTC and Supplements. Drugs A drug is a substance other than food that changes the way the body or mind functions. People use drugs.
Copyright © 2013, 2010, 2006, 2002 by Saunders, an imprint of Elsevier Inc. Care of Patients with Malnutrition and Obesity.
Welcome To Pure Tablets. Reasons Favoring Obesity Imbalanced diet, consumption of fat products and lack of physical activities are some of the important.
Focus on Obesity NUR 171 Copyright © 2011, 2007 by Mosby, Inc., an affiliate of Elsevier Inc.
R1. 이정미 / prof. 이상열. INTRODUCTION Type 2 diabetes is a major risk factor for cardiovascular disease The presence of both type 2 diabetes and.
1 Core Defects of Type 2 Diabetes Targeting Mechanisms for a Comprehensive Approach 1 Part 4 of 4.
Fiona Chan Specialist Dietitian Weight Management and Bariatrics Salford Royal Hospital.
OBESITY WORKSHOP.
Melanie Jaeger T4 Tutoring.
Drugs for Weight Loss 1.
Weight Loss Supplements
Obesity.
Neal B, et al. Diabetes Care 2015;38:403–411
Cardiovascular System
WEIGHT MANAGEMENT.
WEIGHT MANAGEMENT PHARMACOTHERAPY.
WEIGHT MANAGEMENT.
Clinical pharmacy laboratory/4 th Class Anemias and blood disorders
Lecture 3 Endocrine and Metabolic Disorders “Obesity”
Introduction to Clinical Pharmacology Chapter 48 Urinary Tract Anti-Infectives and Other Urinary Drugs.
Cholinesterase Inhibitors: Actions and Uses
Obesity Eppie Habashi.
Section overview: Cardiometabolic risk reduction
Medical Management of Obesity
OBESITY Paul Bolton.
Section 6: Update on lipid treatment guidelines
POLYPHARMACY.
Presentation transcript:

Medicine used in the Treatment of Obesity Elaine Neil Lead Pharmacist North Aberdeenshire LCHP

At one time 3 medicines licensed Orlistat Xenical - POM Alli - OTC

Orlistat Promotes loss of weight by preventing the digestion and absorption of fat Inhibitor of GI lipases acting in stomach and small intestine Reduces absorption of dietary fat by around 25-30% The unabsorbed fat is excreted in the stool.

Contraindications See BNF/SPC Hypersensitivity Chronic malabsorption Cholestasis Breast-feeding Caution in pregnant women The effect of orlistat in patients with hepatic and/or renal impairment, children and elderly patients has not been studied.

Side – effects See BNF/SPC Liquid or oily stools / Oily leakage from rectum Flatulence and Bloating/ abdominal pain Faecal urgency Faecal incontinence Dyspepsia Menstrual disturbances Headache Tooth disorder Anxiety Gingival disorder Fatigue Influenza Respiratory infection Urinary tract infection Hypoglycaemia

Drug Interactions See BNF/SPC Ciclosporin Anti-epileptics Fat soluble vitamins Amiodarone Levothyroxine Warfarin – monitor INR Oral contraceptives – diarrhoea

Orlistat - Xenical Dose 120mg taken with water immediately before, during or up to one hour after main meals. Max dose 360mg daily. Doses above 120 mg three times daily have not been shown to provide additional benefit.

Orlistat Take with calorie controlled diet, 30% calories from fat, distributed over 3 main meals. Omit dose if no main meal taken or no fat content. Increase in faecal fat 24 to 48 hours after dosing, levels return to pre-treatment levels, within 48 - 72 hours.

Eligible Patients BMI 30kg/m2 or greater BMI 28kg/m2 or greater with risk factors diabetes coronary heart disease hypertension hypercholestraemia

Additional “treatment” Orlistat must be prescribed in conjunction with other measures to support weight loss Diet modification Increase in physical activity Behaviour modification Appropriate support and encouragement

Weight Monitoring Serious attempts to lose weight before starting Monitor weight loss during treatment Weight loss – 5% over 3 months (lower in patients with type 2 diabetes)

Weight Monitoring Treatment with orlistat should be discontinued after 12 weeks if patients have not lost at least 5 % of the body weight measured at the start of therapy. Stop therapy if weight loss inadequate May get weight gain on stopping Long-term maintenance of weight loss after a period of obesity is difficult and often unsuccessful, and thus may require sustained support.

Outcomes Pooled data from five 2 year studies with orlistat and a hypocaloric diet showed that 37 % of orlistat patients and 19 % of placebo patients demonstrated a loss of at least 5 % of their baseline body weight after 12 weeks of treatment. Of these, 49 % of orlistat treated patients and 40 % of placebo treated patients went on to lose 10 % of their baseline body weight at one year. Overall, after one year of treatment, the percentage of patients taking 120 mg orlistat who lost 10 % or more of their body weight was 20 % compared to 8 % of patients taking placebo. The mean difference in weight loss with the drug compared to placebo was 3.2 kg.

Xenical – prescription (POM) Xenical 120mg capsules

Alli – over the counter (OTC) Alli 60mg capsules Maximum 60mg three times daily Use for 6 months Discard any capsules stored in the carry case for more than one month.

Costs Orlistat (Xenical) – 120mg x 3 daily 28 days supply £31.63 Alli 60mg x 3 daily 28 days supply £15- £35 Pharmacy or Internet supply

NHS Grampian Spend

NHS Grampian Spend 2010/11 9126 prescriptions £338,643

NHS Grampian Spend

NHS Grampian Spend